US 12,441,797 B2
Anti-FC ϵ-R1 α (FCϵR1α) antibodies, bispecific antigen-binding molecules that bind FCϵR1α and CD3, and uses thereof
Jamie M. Orengo, Cortlandt Manor, NY (US); Andre Limnander, New York, NY (US); Jee H. Kim, Ardsley, NY (US); and Andrew J. Murphy, Tarrytown, NY (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Jan. 12, 2023, as Appl. No. 18/153,522.
Application 18/153,522 is a division of application No. 16/547,910, filed on Aug. 22, 2019, granted, now 11,578,127.
Claims priority of provisional application 62/721,921, filed on Aug. 23, 2018.
Prior Publication US 2023/0331845 A1, Oct. 19, 2023
Int. Cl. C07K 16/28 (2006.01)
CPC C07K 16/2809 (2013.01) [C07K 16/283 (2013.01)] 14 Claims
 
1. A method for treating a disease or disorder associated with FcεR1α expression and/or signaling in a subject, wherein the disease or disorder associated with FcεR1α expression and/or signaling is an allergic disease or condition, a mast cell activation disorder, or mastocytosis, the method comprising administering to the subject a bispecific antigen-binding molecule comprising (i) a first antigen-binding domain that specifically binds human CD3, and (i) a second antigen-binding domain that specifically binds human and/or cynomolgus FcεR1α; wherein:
the first antigen-binding domain comprises the heavy and light chain CDRs of an HCVR/LCVR amino acid sequence pair of SEQ ID NO: 42/26; and
the second antigen-binding domain comprises the heavy and light chain CDRs of an HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2/26, 10/26, and 18/26,
wherein the CDRs are identified by the Kabat definition, the Chothia definition, or the AbM definition.